Gilead Sciences (GILD) News Today $108.22 -0.58 (-0.53%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$109.00 +0.78 (+0.72%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Gilead Sciences Down Today?Toggle Visibility of Why Is Gilead Sciences Down Today?Gilead Sciences, Inc. (NASDAQ: GILD) news summary for the past 24–36 hours: Positive Sentiment: Gilead partnered with singer Tamar Braxton to raise awareness of HIV prevention via its PrEP program, boosting the company’s public profile and potential uptake of its preventive therapies. Tamar Braxton Is Raising Awareness About The Power Of PrEP Under Her New Partnership With Gilead Sciences Positive Sentiment: An updated study on sacituzumab govitecan highlighted new data and market implications for Gilead’s cancer‐targeting antibody-drug conjugate, underlining potential revenue upside if trial outcomes remain strong. Gilead Sciences’ New Study on Sacituzumab Govitecan: Market Implications and Study Insights Positive Sentiment: Leerink Partnrs raised its Q3 2025 EPS estimate for Gilead to $2.37 from $2.26, reflecting improved near-term earnings expectations. Leerink Partnrs Raises Q3 2025 EPS Estimate for Gilead Sciences Neutral Sentiment: A new HIV 7MM drug forecast report projects the market to reach $32.1 billion by 2033, with Gilead poised to remain the leading player—underscoring its entrenched HIV franchise. Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 Neutral Sentiment: Gilead has been flagged by Zacks.com as one of the most-watched medical stocks, reflecting heightened investor interest but no direct catalyst reported. Gilead Sciences, Inc. (GILD) is Attracting Investor Attention Neutral Sentiment: Another Zacks article on medical stocks mentioned Gilead in a broader earnings-beat screen, but without company-specific forecasts or drivers. These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Negative Sentiment: Leerink Partnrs cut its Q2 2025 EPS forecast for Gilead to $1.91 from $2.25, signaling softer near-term earnings expectations. Gilead Sciences Q2 EPS Estimate Lowered by Leerink Partnrs Negative Sentiment: Pomerantz LLP launched an investor investigation into Gilead over undisclosed claims, introducing potential legal and financial risk. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD Negative Sentiment: Gilead’s CFO, Andrew Dickinson, sold 2,500 shares for about $277,575, reducing his stake by 1.5%, which may raise governance or insider-confidence concerns. Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $277,575.00 in Stock Posted 1+ days agoAI Generated. May Contain Errors. GILD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period AustralianSuper Pty Ltd Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)July 19 at 11:04 AM | marketbeat.comSouth Dakota Investment Council Sells 80,827 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)July 19 at 10:39 AM | marketbeat.comFountainhead AM LLC Purchases New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)July 19 at 10:27 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Impact Partnership Wealth LLCJuly 19 at 10:03 AM | marketbeat.comAtle Fund Management AB Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)July 19 at 9:13 AM | marketbeat.comGilead Sciences’ New Study on Sacituzumab Govitecan: Market Implications and Study InsightsJuly 18 at 12:57 PM | tipranks.comYeomans Consulting Group Inc. Purchases New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)July 18 at 10:06 AM | marketbeat.comCommerzbank Aktiengesellschaft FI Buys 2,863 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)July 18 at 8:58 AM | marketbeat.comConcord Wealth Partners Has $131,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)July 18 at 8:23 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Verdence Capital Advisors LLCJuly 18 at 7:21 AM | marketbeat.comEdgestream Partners L.P. Has $2.06 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)July 18 at 5:04 AM | marketbeat.comHuman Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading PlayerJuly 17 at 11:06 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILDJuly 17 at 10:00 AM | prnewswire.comForum Financial Management LP Sells 6,286 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)July 17 at 9:14 AM | marketbeat.comBailard Inc. Sells 6,801 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)July 17 at 8:18 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $277,575.00 in StockJuly 17 at 6:34 AM | insidertrades.comGilead Sciences Q2 EPS Estimate Lowered by Leerink PartnrsJuly 17 at 2:37 AM | americanbankingnews.comInsider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells 2,500 Shares of StockJuly 16, 2025 | marketbeat.comInsider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) Insider Sells 3,000 Shares of StockJuly 16, 2025 | marketbeat.comQ1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics SegmentJuly 16, 2025 | msn.comWhy Merck Is A Better Dividend Stock Than Gilead SciencesJuly 16, 2025 | seekingalpha.comGilead Sciences Advances in Triple-Negative Breast Cancer TreatmentJuly 16, 2025 | tipranks.comTriasima Portfolio Management inc. Purchases New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)July 16, 2025 | marketbeat.comHere's Why Gilead Sciences (GILD) Fell More Than Broader MarketJuly 16, 2025 | msn.comVictory Capital Management Inc. Sells 580,550 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)July 16, 2025 | marketbeat.com5,638 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Bridgewater Advisors Inc.July 16, 2025 | marketbeat.comQ2 EPS Estimates for Gilead Sciences Reduced by AnalystJuly 16, 2025 | marketbeat.comOVERSEA CHINESE BANKING Corp Ltd Sells 3,962 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)July 16, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Director Jeffrey Bluestone Sells 5,000 SharesJuly 16, 2025 | insidertrades.comStephens Inc. AR Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)July 16, 2025 | marketbeat.comGILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law FirmJuly 16, 2025 | prnewswire.comLeerink Partnrs Comments on Gilead Sciences Q3 EarningsJuly 16, 2025 | americanbankingnews.comJeffrey Bluestone Sells 5,000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) StockJuly 15, 2025 | marketbeat.comGilead reaches $202M settlement over HIV drug speaker programJuly 15, 2025 | msn.comGilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income NationsJuly 15, 2025 | msn.comBernstein Maintains Buy Rating on Gilead Sciences (GILD) StockJuly 15, 2025 | insidermonkey.comKornitzer Capital Management Inc. KS Sells 5,189 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)July 15, 2025 | marketbeat.comWealthfront Advisers LLC Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)July 15, 2025 | marketbeat.comQ3 EPS Forecast for Gilead Sciences Increased by AnalystJuly 15, 2025 | marketbeat.comCornercap Investment Counsel Inc. Has $1.62 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)July 15, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Apollon Wealth Management LLCJuly 15, 2025 | marketbeat.comSigma Planning Corp Lowers Position in Gilead Sciences, Inc. (NASDAQ:GILD)July 15, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Bleakley Financial Group LLCJuly 15, 2025 | marketbeat.comGILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law FirmJuly 14, 2025 | businesswire.comWHO recommends Gilead's twice-yearly injection for HIV preventionJuly 14, 2025 | reuters.comGilead Sciences Target of Unusually High Options Trading (NASDAQ:GILD)July 14, 2025 | marketbeat.comGilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025July 14, 2025 | businesswire.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Leo Wealth LLCJuly 14, 2025 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bogart Wealth LLCJuly 14, 2025 | marketbeat.comAsset Dedication LLC Has $1.42 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)July 13, 2025 | marketbeat.com Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address GILD Media Mentions By Week GILD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼0.850.59▲Average Medical News Sentiment GILD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼6835▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LGND News Today MRNA News Today REGN News Today VIR News Today VRTX News Today ABBV News Today MRK News Today PFE News Today AMGN News Today ALNY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GILD Stock Alerts